Search Results

AIM ImmunoTech Inc. today announced that it has received authorization from the Erasmus Medical Center (“Erasmus MC”) Ethics Committee to open a European site for the ongoing Phase 2 study (“AMP-270”) of Ampligen as a therapy for locally advanced pancreatic cancer.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial.

Curiox Biosystems is pleased to announce the establishment of the Curiox Innovation Center for the Curiox C-FREE™ Pluto LT System at the Human Immune Monitoring Center (HIMC) at Stanford University.

Ractigen Therapeutics announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University.

Hackensack Meridian Hackensack University Medical Center, a center of excellence and an international leader in robotic-assisted surgery, was selected to be one of only 14 centers in the world, and the only in New Jersey, New York and Connecticut, to acquire the Intuitive Surgical da Vinci 5 multiport surgical system.

University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia, and University Health Alliance, a multi-disciplinary practice focusing on prevention and coordinated care, announce the opening of their High-Risk GI Clinic.

Deepcell today announced the first commercial placement of the REM-I platform at Erasmus Medical Center in Rotterdam.